Clinical trials recruiting for Advanced Solid Tumor
61
Recruiting trials
39
US states with sites
28
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Pembrolizumab | 5 |
| Carboplatin | 3 |
| Fulvestrant | 3 |
| Olaparib | 3 |
| Pembrolizumab (KEYTRUDA®) | 3 |
| Cemiplimab | 2 |
| Cisplatin | 2 |
| Keytruda | 2 |
| Letrozole | 2 |
| Nivolumab | 2 |
| Paclitaxel | 2 |
| Palbociclib | 2 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 36 |
| California | 27 |
| Florida | 25 |
| New York | 24 |
| Ohio | 19 |
| Tennessee | 18 |
| Michigan | 15 |
| Pennsylvania | 15 |
| Virginia | 15 |
| Arizona | 14 |
| Massachusetts | 13 |
| Colorado | 12 |
Top cities
Houston, Texas 22New York, New York 22Nashville, Tennessee 18San Antonio, Texas 16Fairfax, Virginia 14Boston, Massachusetts 12Cleveland, Ohio 12Dallas, Texas 10St Louis, Missouri 10Grand Rapids, Michigan 9
Self-screener
Recruiting trials
- 64Cu-GRIP B in Patients With Advanced Malignancies
- A Beta-only IL-2 ImmunoTherapY Study
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
- A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
- A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
- A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- A Study of DB-1310 in Advanced/Metastatic Solid Tumors
- A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- A Study of IDP-001 in Advanced or Metastatic Solid Tumors
- A Study of KK2269 in Adult Participants With Solid Tumors
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
- A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- HEC169096 in Participants With Advanced Solid Tumors
- JMT106 Injection in the Treatment of Advanced Solid Tumors
- M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
- Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
- Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
- SW-682 in Advanced Solid Tumors
- Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
- Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
- Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
- Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Study of AVZO-021 in Patients With Advanced Solid Tumors
- Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
- Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
- Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
- Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
- TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- VSV-02 Compassionate Use in Advanced Solid Tumors
Related conditions
Trials recruiting for Advanced Solid Tumor often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Breast cancer 2239Melanoma 487Non-small cell lung cancer 507Metastatic Solid Tumor 22Pancreatic cancer 870Prostate cancer 1234Colorectal cancer 1359Ovarian cancer 118Endometrial cancer 68
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Advanced Solid Tumor trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.